CLINICAL TRIALS PROFILE FOR RITUXAN

Biosimilar Clinical Trials for RITUXAN

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04323956 ↗	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-06-15	This phase I/Ib trial studies the side effects and best dose of parsaclisib plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP]) and to see how well they work compared with R-CHOP alone in treating patients with newly diagnosed, high risk diffuse large B-cell lymphoma. Parsaclisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and vincristine sulfate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. It is not yet known if giving parsaclisib and R-CHOP together works better than R-CHOP alone in treating patients with high risk diffuse large B-cell lymphoma.
NCT04323956 ↗	Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma	Recruiting	Mayo Clinic	Phase 1	2020-06-15	This phase I/Ib trial studies the side effects and best dose of parsaclisib plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone [R-CHOP]) and to see how well they work compared with R-CHOP alone in treating patients with newly diagnosed, high risk diffuse large B-cell lymphoma. Parsaclisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and vincristine sulfate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. It is not yet known if giving parsaclisib and R-CHOP together works better than R-CHOP alone in treating patients with high risk diffuse large B-cell lymphoma.
NCT04555811 ↗	FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL	Recruiting	Masonic Cancer Center, University of Minnesota	Phase 1	2020-09-22	This is a Phase I multi-center study to evaluate the safety of FT596 when given with rituximab as relapse prevention in patients who have undergone an autologous hematopoietic stem cell transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.

All Clinical Trials for RITUXAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003204 ↗	Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1998-03-01	Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy followed by rituximab or observation in treating patients who have stage III or stage IV low-grade non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known which regimen of combination chemotherapy, with or without rituximab, is more effective for non-Hodgkin's lymphoma
NCT00003397 ↗	Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	Completed	University of Maryland Greenebaum Cancer Center	Phase 2	1998-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy and rituximab in treating patients with non-Hodgkin's lymphoma.
NCT00003397 ↗	Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma	Completed	University of Maryland	Phase 2	1998-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy and rituximab in treating patients with non-Hodgkin's lymphoma.

Clinical Trial Conditions for RITUXAN

Condition Name

Condition Name for RITUXAN
Intervention	Trials
Lymphoma	117
Leukemia	59
Chronic Lymphocytic Leukemia	53

Condition MeSH

Condition MeSH for RITUXAN
Intervention	Trials
Lymphoma	383
Lymphoma, Non-Hodgkin	167
Leukemia	149

Clinical Trial Locations for RITUXAN

Trials by Country

Trials by Country for RITUXAN
Location	Trials
Australia	66
France	57
Germany	42
Poland	38
United Kingdom	32

Trials by US State

Trials by US State for RITUXAN
Location	Trials
Texas	194
New York	130
California	128
Ohio	106
Illinois	84

Clinical Trial Progress for RITUXAN

Clinical Trial Phase

Clinical Trial Phase for RITUXAN
Clinical Trial Phase	Trials
PHASE1	1
Phase 4	14
Phase 3	64

Clinical Trial Status

Clinical Trial Status for RITUXAN
Clinical Trial Phase	Trials
Completed	298
Recruiting	103
Terminated	94

Clinical Trial Sponsors for RITUXAN

Sponsor Name

Sponsor Name for RITUXAN
Sponsor	Trials
National Cancer Institute (NCI)	183
M.D. Anderson Cancer Center	125
Genentech, Inc.	79

Sponsor Type

Sponsor Type for RITUXAN
Sponsor	Trials
Other	637
Industry	422
NIH	217

Last updated: July 26, 2026

RITUXAN (rituximab): Latest clinical-trials update, market performance, and near-term launch projections by biosimilar and indication

What clinical trials are ongoing for Rituxan (rituximab) and what results matter for market trajectory?

Rituxan’s clinical development has shifted from broad, label-expansion trials toward combination strategies, retreatment paradigms, and line-optimization across B-cell malignancies and immune-mediated diseases. The market impact is driven less by new “first-in-class” signals and more by incremental survival endpoints, durability of response, and steroid-sparing or chemo-sparing protocols that determine uptake in relapsed and refractory settings.

Which indications anchor Rituxan’s ongoing trial mix (and why they drive revenue)?

The highest commercial relevance remains:

• Non-Hodgkin lymphoma (NHL), especially diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
• Rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and other off-onc label areas.
• Autoimmune and B-cell targeted combinations that can defend share against biosimilars by improving outcomes in practice.

What trial endpoints typically determine payer and guideline uptake for rituximab regimens?

For market forecasting, the endpoints that move prescribing patterns are:

• Progression-free survival (PFS) and overall survival (OS) in lymphoma.
• Time to next treatment (TTNT) and durability of response in maintenance strategies.
• MRD-negative/negative conversion metrics where used as surrogates for escalation or de-escalation.
• Flare rates and steroid exposure reduction in autoimmune disease.

How do combination and sequencing trials affect Rituxan’s competitive position vs biosimilars?

Rituxan biosimilar entry raises unit-price pressure. Combination trials matter because they create “regimen lock-in” where prescribers adopt specific protocols. Protocol standardization can partially offset generic/biosimilar price erosion if the trial regimen matches real-world care pathways.

What is the current market size for Rituxan (rituximab) and what share is at risk from biosimilars?

Rituxan’s revenue is exposed to systematic price compression from rituximab biosimilars across major geographies where interchangeability and formulary adoption are supported.

Where is Rituxan most exposed to biosimilar cannibalization?

• US: biosimilar penetration is strongest where payers run aggressive formulary switches and where biosimilar manufacturers have broad distribution and contracting leverage.
• EU5 and UK: adoption varies by country procurement rules and hospital tender practices.
• ROW: uptake depends on reimbursement policy and procurement structures.

How should “market projection” be modeled for Rituxan given biosimilar dynamics?

A standard projection approach uses three layers:

1. Baseline demand by indication and line of therapy (volume).
2. ASP erosion driven by biosimilar penetration and contracting.
3. Mix shift as regimens move toward less immunochemotherapy-intensive pathways over time.

With rituximab, the dominant variable in short-to-mid horizon projections is ASP erosion driven by biosimilar share, since rituximab remains entrenched as a B-cell backbone.

When do Rituxan patents and exclusivity lose key protection, and how does that time window map to market erosion?

Rituxan faces an “exclusivity stack” that includes:

• Primary patent term expiration.
• US regulatory exclusivity and patent term adjustments.
• Additional formulation, method-of-use, and manufacturing process protections (where present).

What matters most for launch risk timing (Rituxan ecosystem)?

• US: the timing of first generic/biosimilar litigation and settlement cycles that determine enforceable windows.
• EU: timing of supplementary protections and market-entry authorizations translated into tender outcomes.
• Practical reality: even after legal exclusivity ends, contracting and hospital acceptance control the pace of volume migration.

What is the Orange Book status of Rituxan (rituximab) and what does it imply for generic/biosimilar entry?

Rituxan is a biologic, so the Orange Book does not control the biosimilar path in the same way it controls small molecules. FDA biologics licensing status is instead captured through the BLA/biosimilar framework under the Biologics Price Competition and Innovation Act, with reference product designation and biosimilar approval packages.

What controls biosimilar entry and uptake more than “Orange Book” listings?

• BLA pathway labeling and interchange considerations.
• Institute of formulary coverage and tender outcomes.
• Patient and provider comfort with non-reference products, which improves after post-approval safety data accumulation.

Which rituximab biosimilars most threaten Rituxan revenue, and how do they compare on label and switching?

Market threat is concentrated in biosimilars that:

• Have broad label similarity across the reference product indications.
• Are priced aggressively enough to win formulary contracts.
• Have robust manufacturing scale and supply continuity.

What comparison factors determine switching from Rituxan to biosimilars?

• Hospital procurement and contracting terms (tender price tiers).
• Infusion protocol compatibility (premedication and administration guidance).
• Pharmacovigilance requirements and perceived safety parity.
• Geographic adoption sequencing and payer policies.

What patent litigation and settlements affect Rituxan (rituximab) biosimilar launch risk?

Rituximab litigation has historically included patent disputes around:

• Methods of use.
• Formulations and manufacturing-related patents.
• Process and cell line-related protections (where applicable).

How does litigation timeline translate into market outcomes?

• A stay can delay launch, keeping reference product revenue elevated.
• A settlement can narrow entry timing windows and create “carve-outs” by formulation, indication, or time.
• Even after entry, launch volume can be staged based on contracting.

What formulations and dosing regimens are protected for Rituxan, and how do they shape biosimilar interchange?

For rituximab, practical regimen considerations include:

• Infusion schedule and dose intensity.
• Premedication and infusion center protocols.
• Indication-specific dosing and re-treatment rules.

Why formulation and regimen details matter commercially

When clinicians standardize infusion center protocols to align with reference product workflows, switching can slow. Biosimilars that can mirror administration workflows move faster in uptake.

How strong is the patent estate for Rituxan vs key competitors (biosimilars) and what is the “barrier to entry”?

Barriers to entry are less about absolute patent count and more about:

• Enforceable claims that remain at the time biosimilars attempt market entry.
• Indication-specific or method-of-use claims that can block “market-ready” label parity.
• Practical constraints that limit how biosimilars contract at scale.

What generic and biosimilar entry risks exist for Rituxan in the next 12–36 months?

The next window is driven by:

• Additional biosimilar launches or expanded coverage if manufacturing and supply scale support it.
• Tender cycles that force switching even when uptake had been partial.
• Category-level payer policies affecting oncology and autoimmune drug budgets.

What would accelerate Rituxan revenue decline?

• Faster formulary substitution and mandatory switching programs.
• Larger payer networks standardizing biosimilar procurement.
• Any dosing or administration standardization that reduces operational resistance to biosimilars.

What could slow cannibalization?

• Regimen-specific preferences in subpopulations where clinicians remain anchored to established infusion workflows.
• Institutional inertia, especially in centers with established rituximab protocols.

How does Rituxan’s performance compare with other anti-CD20 therapies (obinutuzumab, ofatumumab) for market share outlook?

Competitive positioning by efficacy and tolerability affects prescribing:

• In FL and certain lymphoma contexts, anti-CD20 selection can shift by trial results and toxicity profiles.
• In CLL and immunochemotherapy combinations, choice is driven by regimen norms and patient characteristics.

What matters for Rituxan projection when patients can switch to other anti-CD20 options?

• Comparative effectiveness in real-world cohorts.
• Treatment sequencing after prior exposure to anti-CD20.
• Payer preference for the lowest net cost regimen class.

What regulatory milestones and FDA actions most affect Rituxan’s future demand?

Regulatory actions that shape demand include:

• Label updates that expand patient populations or refine retreatment schedules.
• Biosimilar naming and interchange-related guidance that improves switching confidence.
• Risk-management communications that influence center-level adoption.

Key takeaways

• Rituxan demand remains driven by established B-cell malignancy and autoimmune indications, but revenue projection is dominated by biosimilar-driven ASP erosion rather than demand destruction.
• Clinical trial value is most tied to regimen durability, PFS/OS improvements, and standard-of-care optimization that can sustain volume and resist substitution.
• Market risk concentrates on biosimilar penetration and tender-driven switching across major hospital systems.
• Near-term projections should treat legal timing as baseline and assume contracting will control actual reference product volume migration pace.

FAQs

1. What does a biosimilar switch typically do to net pricing for rituximab in US hospital formularies?
2. Which Rituxan indications are most likely to retain higher pricing due to regimen protocol lock-in?
3. How do administration and infusion-center workflows affect biosimilar uptake versus purely label-driven acceptance?
4. What anti-CD20 sequencing factors reduce substitution risk from rituximab to competing agents?
5. How do litigation settlement terms influence timing of biosimilar launches by indication?

References

1. FDA. Biosimilars. https://www.fda.gov/drugs/biosimilars
2. FDA. Purple Book: Lists of Licensed Biological Products, Including Biosimilars. https://purplebooksearch.fda.gov/
3. U.S. Congress. Biologics Price Competition and Innovation Act (BPCIA). https://www.congress.gov/